JP2020530293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530293A5 JP2020530293A5 JP2020506964A JP2020506964A JP2020530293A5 JP 2020530293 A5 JP2020530293 A5 JP 2020530293A5 JP 2020506964 A JP2020506964 A JP 2020506964A JP 2020506964 A JP2020506964 A JP 2020506964A JP 2020530293 A5 JP2020530293 A5 JP 2020530293A5
- Authority
- JP
- Japan
- Prior art keywords
- place
- seq
- sequence
- ala
- polypeptide comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 387
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 387
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 387
- 239000000539 dimer Substances 0.000 claims description 45
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 7
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 6
- 230000008499 blood brain barrier function Effects 0.000 claims description 6
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 6
- 210000003038 endothelium Anatomy 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000031998 transcytosis Effects 0.000 claims description 2
- 230000000447 dimerizing effect Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543658P | 2017-08-10 | 2017-08-10 | |
| US62/543,658 | 2017-08-10 | ||
| US201762583314P | 2017-11-08 | 2017-11-08 | |
| US62/583,314 | 2017-11-08 | ||
| USPCT/US2018/018371 | 2018-02-15 | ||
| PCT/US2018/018371 WO2018152326A1 (en) | 2017-02-17 | 2018-02-15 | Engineered transferrin receptor binding polypeptides |
| PCT/US2018/046199 WO2019032955A1 (en) | 2017-08-10 | 2018-08-10 | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530293A JP2020530293A (ja) | 2020-10-22 |
| JP2020530293A5 true JP2020530293A5 (https=) | 2021-09-16 |
| JP7280241B2 JP7280241B2 (ja) | 2023-05-23 |
Family
ID=65272509
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506964A Active JP7280241B2 (ja) | 2017-08-10 | 2018-08-10 | 操作されたトランスフェリン受容体結合ポリペプチド |
| JP2020507090A Pending JP2020530465A (ja) | 2017-08-10 | 2018-08-10 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2023107814A Pending JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2025090730A Pending JP2025120209A (ja) | 2017-08-10 | 2025-05-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507090A Pending JP2020530465A (ja) | 2017-08-10 | 2018-08-10 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2023107814A Pending JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2025090730A Pending JP2025120209A (ja) | 2017-08-10 | 2025-05-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20200369746A1 (https=) |
| EP (2) | EP3665192B1 (https=) |
| JP (4) | JP7280241B2 (https=) |
| CN (2) | CN111094336A (https=) |
| CA (2) | CA3072035A1 (https=) |
| DK (1) | DK3665192T5 (https=) |
| ES (1) | ES2956062T3 (https=) |
| FI (1) | FI3665192T3 (https=) |
| HR (1) | HRP20231118T1 (https=) |
| HU (1) | HUE063021T2 (https=) |
| LT (1) | LT3665192T (https=) |
| MD (1) | MD3665192T2 (https=) |
| PL (1) | PL3665192T3 (https=) |
| PT (1) | PT3665192T (https=) |
| RS (1) | RS64584B1 (https=) |
| SI (1) | SI3665192T1 (https=) |
| SM (1) | SMT202300347T1 (https=) |
| TW (1) | TWI821197B (https=) |
| WO (2) | WO2019032955A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019016989A2 (pt) | 2017-02-17 | 2020-05-26 | Denali Therapeutics Inc. | Polipeptídeos de ligação ao receptor de transferrina manipulados |
| AU2018345303B2 (en) | 2017-10-02 | 2025-09-18 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| KR20210074279A (ko) * | 2018-08-22 | 2021-06-21 | 데날리 테라퓨틱스 인크. | 항-her2 폴리펩타이드 및 이의 사용방법 |
| PH12021552002A1 (en) | 2019-02-20 | 2022-09-19 | Denali Therapeutics Inc | Anti-trem2 antibodies and methods of use thereof |
| CA3165846A1 (en) | 2019-12-23 | 2021-07-01 | Denali Therapeutics Inc. | Progranulin variants |
| PE20221465A1 (es) * | 2020-01-13 | 2022-09-21 | Denali Therapeutics Inc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| CN115361972A (zh) * | 2020-02-19 | 2022-11-18 | 戴纳立制药公司 | 工程化抗her2双特异性蛋白 |
| PE20231931A1 (es) | 2020-10-14 | 2023-12-01 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas |
| EP4396231A1 (en) | 2021-09-01 | 2024-07-10 | Biogen MA Inc. | Anti-transferrin receptor antibodies and uses thereof |
| AU2022428997A1 (en) * | 2021-12-31 | 2024-08-15 | Imnewrun, Inc. | Blood-brain barrier permeable fusion protein and uses thereof |
| IL318625A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle |
| JP2025525792A (ja) | 2022-07-29 | 2025-08-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | トランスフェリン受容体１に対して再標的化されるウイルス粒子 |
| CA3263494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | ANTI-TFR FUSIONS: PAYLOAD AND THEIR METHODS OF USE |
| AU2023316646A1 (en) | 2022-07-29 | 2024-12-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
| WO2024130116A2 (en) * | 2022-12-16 | 2024-06-20 | Denali Therapeutics Inc. | Methods and compositions related to engineered transferrin receptor‑binding molecules |
| AU2024317483A1 (en) | 2023-07-28 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
| WO2026052652A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
| WO2026052654A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7087000A (en) * | 1999-08-30 | 2001-03-26 | New York University School Of Medicine | Crystal structures of domains of receptor protein tyrosine kinases and their ligands |
| CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| AR084020A1 (es) * | 2010-11-30 | 2013-04-17 | Genentech Inc | Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| RU2711552C2 (ru) * | 2012-08-29 | 2020-01-17 | Ф. Хоффманн-Ля Рош Аг | Шаттл для гематоэнцефалического барьера |
| WO2014189973A2 (en) * | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| CA2932547C (en) * | 2014-01-06 | 2023-05-23 | F. Hoffmann-La Roche Ag | Monovalent blood brain barrier shuttle modules |
| SG11201609274SA (en) * | 2014-05-22 | 2016-12-29 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| WO2016077840A2 (en) * | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS |
| EP3221361B1 (en) * | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
| MX391086B (es) * | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
-
2018
- 2018-08-10 SM SM20230347T patent/SMT202300347T1/it unknown
- 2018-08-10 CA CA3072035A patent/CA3072035A1/en active Pending
- 2018-08-10 PT PT187565312T patent/PT3665192T/pt unknown
- 2018-08-10 PL PL18756531.2T patent/PL3665192T3/pl unknown
- 2018-08-10 DK DK18756531.2T patent/DK3665192T5/da active
- 2018-08-10 EP EP18756531.2A patent/EP3665192B1/en active Active
- 2018-08-10 FI FIEP18756531.2T patent/FI3665192T3/fi active
- 2018-08-10 CN CN201880053177.4A patent/CN111094336A/zh active Pending
- 2018-08-10 ES ES18756531T patent/ES2956062T3/es active Active
- 2018-08-10 MD MDE20200637T patent/MD3665192T2/ro unknown
- 2018-08-10 JP JP2020506964A patent/JP7280241B2/ja active Active
- 2018-08-10 HR HRP20231118TT patent/HRP20231118T1/hr unknown
- 2018-08-10 LT LTEPPCT/US2018/046199T patent/LT3665192T/lt unknown
- 2018-08-10 TW TW107128067A patent/TWI821197B/zh active
- 2018-08-10 SI SI201830986T patent/SI3665192T1/sl unknown
- 2018-08-10 JP JP2020507090A patent/JP2020530465A/ja active Pending
- 2018-08-10 EP EP18843180.3A patent/EP3665194A4/en active Pending
- 2018-08-10 RS RS20230817A patent/RS64584B1/sr unknown
- 2018-08-10 CA CA3072051A patent/CA3072051A1/en active Pending
- 2018-08-10 WO PCT/US2018/046199 patent/WO2019032955A1/en not_active Ceased
- 2018-08-10 HU HUE18756531A patent/HUE063021T2/hu unknown
- 2018-08-10 CN CN201880063660.0A patent/CN111148757B/zh active Active
- 2018-08-10 WO PCT/US2018/046337 patent/WO2019033046A1/en not_active Ceased
-
2020
- 2020-02-05 US US16/782,669 patent/US20200369746A1/en not_active Abandoned
- 2020-02-05 US US16/782,984 patent/US20200289627A1/en not_active Abandoned
-
2023
- 2023-02-08 US US18/166,223 patent/US20230381286A1/en active Pending
- 2023-06-30 JP JP2023107814A patent/JP2023123757A/ja active Pending
- 2023-09-08 US US18/464,025 patent/US20240024432A1/en not_active Abandoned
-
2025
- 2025-05-30 JP JP2025090730A patent/JP2025120209A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530293A5 (https=) | ||
| FI3665192T3 (fi) | Muunneltuja transferriinireseptoria sitovia polypeptidejä | |
| US12497462B2 (en) | Anti-CD26 proteins and uses thereof | |
| JP2021514618A5 (https=) | ||
| JP2021020905A5 (https=) | ||
| JP2019521643A5 (https=) | ||
| JP2011501951A5 (https=) | ||
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| JP2020500015A5 (https=) | ||
| JP2017522891A5 (https=) | ||
| AU2012332263A1 (en) | Low density lipoprotein-related protein 6 (LRP6) - half life extender constructs | |
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| JP2019520797A5 (https=) | ||
| RU2017144098A (ru) | Гетеродимеризованный полипептид | |
| JP2014510518A5 (https=) | ||
| KR20140067944A (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| JP2013507115A (ja) | 「終末糖化産物受容体」への結合のためのポリペプチド、さらにはそれを含む組成物及び方法 | |
| JP2018519803A5 (https=) | ||
| JP2010502183A5 (https=) | ||
| JP2019506140A5 (https=) | ||
| JP2021512159A5 (https=) | ||
| Lu et al. | Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2 | |
| CN116925215A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2017509323A5 (https=) | ||
| HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću |